Kolexia
Pierard Laure
Oncologie médicale
Hôpital Hautepierre
Strasbourg, France
43 Activités
33 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Néphrocarcinome Tumeurs du rein Tumeurs de la prostate Carcinomes COVID-19 Métastase tumorale Tumeurs embryonnaires et germinales Adénocarcinome à cellules claires

Industries

Ipsen
9 collaboration(s)
Dernière en 2023
Astellas
7 collaboration(s)
Dernière en 2023
Janssen
6 collaboration(s)
Dernière en 2023
Pfizer
3 collaboration(s)
Dernière en 2023

Dernières activités

GIG-T: Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
Essai Clinique (Gustave-Roussy)   18 octobre 2023
Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
Cancer treatment and research communications   25 juin 2023
COG-PRO: Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
Essai Clinique (Centre François-Baclesse)   10 janvier 2023
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
Breast cancer research and treatment   23 décembre 2022
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Clinical breast cancer   13 octobre 2022
Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   29 avril 2022
Abstract P1-17-07: Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak
2021 San Antonio Breast Cancer Symposium   15 février 2022
286P Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
CN54 Impact of the app-based and nurse-led supportive care program AKO@dom on dose-intensity of oral targeted therapies in patients with metastatic renal cell cancer: A multicentric observational retrospective study
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
319P A propensity score weighted study comparing two versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021